Could a Custom-Made vaccine help control HIV without daily pills?

NCT ID NCT00510497

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small early-phase trial tested a personalized vaccine for HIV made from each patient's own immune cells and inactivated virus. Eleven HIV-positive volunteers who had never taken antiretroviral therapy received the vaccine and then temporarily stopped their regular HIV medications. The main goals were to check safety and see if the vaccine could lower the amount of virus in the blood, potentially allowing people to control HIV without daily pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

autologous dendritic cell vaccine (made from the patient's own immune cells and inactivated HIV)

What this could lead to

If it works, this could point toward a way to control HIV without needing daily antiretroviral drugs, potentially reducing long-term side effects and treatment burden.

What could go wrong

This is a very small, early-phase trial with only 11 participants, so results may not apply broadly. The vaccine may not lower viral load enough, and there is a risk of side effects from the treatment interruption.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States